These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25572478)

  • 1. Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma.
    Witkowska M; Smolewski P
    Immunotherapy; 2015; 7(1):37-46. PubMed ID: 25572478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.
    Koivula S; Valo E; Raunio A; Hautaniemi S; Leppä S
    Oncol Rep; 2011 Apr; 25(4):1183-90. PubMed ID: 21318224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of diffuse large B-cell lymphoma (DLBCL).
    Kubuschok B; Held G; Pfreundschuh M
    Cancer Treat Res; 2015; 165():271-88. PubMed ID: 25655614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse large B-cell lymphoma: current strategies and future directions.
    Cultrera JL; Dalia SM
    Cancer Control; 2012 Jul; 19(3):204-13. PubMed ID: 22710896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quercetin potentiates the antitumor activity of rituximab in diffuse large B-cell lymphoma by inhibiting STAT3 pathway.
    Li X; Wang X; Zhang M; Li A; Sun Z; Yu Q
    Cell Biochem Biophys; 2014 Nov; 70(2):1357-62. PubMed ID: 24902540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State-of-the-art Therapy for Advanced-stage Diffuse Large B-cell Lymphoma.
    Chiappella A; Castellino A; Vitolo U
    Hematol Oncol Clin North Am; 2016 Dec; 30(6):1147-1162. PubMed ID: 27888872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody and immunotherapy in diffuse large B-cell lymphoma.
    Barraclough A; Hawkes EA
    Semin Hematol; 2023 Nov; 60(5):338-345. PubMed ID: 38072722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New agents and regimens for diffuse large B cell lymphoma.
    Wang L; Li LR; Young KH
    J Hematol Oncol; 2020 Dec; 13(1):175. PubMed ID: 33317571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
    Sehn LH; Connors JM
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 1):26-34. PubMed ID: 15934515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up of patients receiving rituximab for diffuse large B cell lymphoma: an overview of systematic reviews.
    Lindenmeyer LP; Hegele V; Caregnato JP; Wüst D; Grazziotin L; Stoll P
    Ann Hematol; 2013 Nov; 92(11):1451-9. PubMed ID: 23748882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostication of diffuse large B-cell lymphoma in the rituximab era.
    Ninan MJ; Wadhwa PD; Gupta P
    Leuk Lymphoma; 2011 Mar; 52(3):360-73. PubMed ID: 21275631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
    Rasmussen PK
    Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches.
    Hernandez-Ilizaliturri FJ; Czuczman MS
    Oncology (Williston Park); 2009 May; 23(6):546-53. PubMed ID: 19544696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
    Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
    Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children.
    Reiter A; Klapper W
    Br J Haematol; 2008 Jul; 142(3):329-47. PubMed ID: 18537979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles.
    Cillessen SA; Meijer CJ; Notoya M; Ossenkoppele GJ; Oudejans JJ
    J Pathol; 2010 Apr; 220(5):509-20. PubMed ID: 20087881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue microarray in a subset of South African patients with DLBCL.
    Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P
    Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
    Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
    Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.